

[Prosigna breast cancer assay, 2/14](#)

written by CAP TODAY

February 18, 2014

February 2014—NanoString Technologies announced the availability of the Prosigna Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of this year.

The Prosigna Assay is an in vitro diagnostic tool that provides a risk category and numerical score for assessing the risk of distant recurrence of disease at 10 years in postmenopausal women with node-negative (stage I or II) or node-positive (stage II) hormone receptor-positive breast cancer. Based on the PAM50 gene signature, the assay measures gene expression levels of RNA extracted from formalin-fixed, paraffin-embedded breast tumor tissue previously diagnosed as invasive breast carcinoma.

[NanoString Technologies](#), 760-539-7417



©2026 CAP TODAY, all rights reserved.